Epidemiology, Management, Quality of Testing and Cost of Syphilis in Germany: A Retrospective Model Analysis

Renata Šmit 1,2*, Nathalie Wojtalewicz 2, Laura Vierbaum 2, Farzin Nourbakhsh 1, Ingo Schellenberg 2,3, Klaus-Peter Hunfeld 1,2† and Benedikt Lohr 1,2‡

1 Northwest Medical Centre, Medical Faculty, Academic Teaching Hospital, Institute for Laboratory Medicine, Microbiology and Infection Control, Goethe University, Frankfurt, Germany, 2 INSTAND e.V. Gesellschaft zur Foerderung der Qualitaetsicherung in Medizinischen Laboratorien e.V, Duesseldorf, Germany, 3 Center of Life Sciences, Institute of Bioanalytical Sciences (IBAS), Anhalt University of Applied Sciences, Bernburg, Germany

Background: A multi-dimensional model can be a useful tool for estimating the general impact of disease on the different sectors of the healthcare system. We chose the sexually transmitted disease syphilis for our model due to the good quality of reported data in Germany.

Methods: The model included gender- and age-stratified incident cases of syphilis (in- and outpatients) provided by a German statutory health insurance company, as well as seroprevalence data on syphilis in first-time blood donors. Age standardized rates were calculated based on the standard German population. The test quality was assessed by extrapolating the number of false-positive and false-negative results based on data from Europe-wide external quality assessment (EQA) schemes. The model analysis was validated with the reported cases and diagnosis-related group (DRG)-statistics from 2010 to 2012. The annual direct and indirect economic burden was estimated based on the outcomes of our model.

Results: The standardized results were slightly higher than the results reported between 2010 and 2012. This could be due to an underassessment of cases in Germany or due to limitations of the dataset. The number of estimated inpatients was predicted with an accuracy of 89.8 %. Results from EQA schemes indicated an average sensitivity of 92.8 % and an average specificity of 99.9 % for the recommended sequential testing for syphilis. Based on our model, we estimated a total average minimal annual burden of €20,292,110 for syphilis on the German healthcare system between 2010 and 2012.

Conclusions: The linking of claims data, results from EQA schemes, and blood donor surveillance can be a useful tool for assessing the burden of disease on the healthcare system. It can help raise awareness in populations potentially at risk for infectious diseases, demonstrate the need to educate potential risk groups, and may help with predictive cost calculations and planning.

Keywords: syphilis, healthcare utilization database, blood donor database, Germany, retrospective model analysis, EQA, economic model
INTRODUCTION

Syphilis is a systemic disease caused by the bacteria *Treponema pallidum*. The pathogen can be transmitted via transplacental transmission, sexual contact with infectious lesions, and blood transfusions (1). Untreated or undetected infections can lead to severe health outcomes (e.g., neurosyphilis) and can even compromise pregnancy outcomes (including stillbirth and congenital syphilis) (2); thus it represents a serious health concern.

While treatment of syphilis is assessable and cost effective, the diagnosis of syphilis is challenging because traditional tools like cultivation and gram staining are not available (3). In addition, the clinical symptoms often indicate more than one possible differential diagnosis result (4, 5). Since the disease tends to manifest inconspicuously, an infection often remains undetected (6), resulting in an underassessment of infections. Currently, most syphilis cases are diagnosed through serological testing (7) and, in Germany, all laboratories are obliged to anonymously report treponemal pallidum positive serological test results to the Robert Koch Institute (RKI) (8). This offers a good insight into incident cases. Syphilis antibodies detected in blood donor samples must also be reported to the RKI (9). Transmission via transfusion has not happened for over 15 years in Germany (10). However, blood donor data is a useful tool in providing information on the seroprevalence of syphilis in the population, making it suitable for monitoring the effects of public health programs (11, 12).

Nevertheless, these sources offer only limited information on some aspects, like treatment patterns and loss of productivity due to sick leave. Claims data from statutory health insurance companies can close this information gap since they reflect real-life healthcare provisions better than clinical trials (13).

Combining different datasets into a model analysis is a helpful tool for developing recommendations and guidelines and for initiating effective public health measures (13).

The aim of this study is to combine cross-validated data from a German statutory health insurance company with information on seroprevalence derived from blood donor screening data from 2010 to 2012 and to conduct an evaluation based on actual data and diagnosis-related group (DRG) statistics, reported during this period. The claims data and blood donor data are used to calculate the reported seroprevalence rates and the corresponding number of blood samples. We only analyzed data on new blood donors as well as cases of insufficiently treated syphilis (syphilis non satis curate) were excluded from this dataset by RKI prior to the analysis (18).

Furthermore, data from Europe-wide external quality assessment (EQA) schemes are used to access the current data on the quality of *in vitro* serological testing of *Treponema pallidum* and its impact on the German healthcare system. These EQA schemes are conducted by INSTAND, one of the three organizations in Germany designated as a reference institution by the German Medical Association.

MATERIALS AND METHODS

Analysis of Health Insurance Datasets

The basic dataset consisted of health insurance data from the German statutory health insurance company Deutsche Angestellten Krankenkasse-Gesundheit (DAK-G) from 2010 to 2012 and covered around 5.8 million people insured during the study period. The relevant international classification of disease (ICD-10-German Modification) for syphilis was used: syphilis (A50. - congenital syphilis, A51.x - early syphilis, A52.x - late syphilis, A53.x - other or unspecified syphilis). Data were available up to December 31, 2012 (Supplementary Tables 1, 2). All analyses were based on anonymized subject-specific data.

The personal data were exclusively handled by DAK-G in accordance with legal data protection requirements. Information on comorbidities was not included in this model, since we wanted to focus on the sole impact of syphilis. The quality of the data was checked for completeness, correct usage of inclusion criteria, and plausibility prior to analysis according to existing standards (14, 15). Incident cases of syphilis diagnosed on an inpatient and outpatient basis in 2010, 2011, and 2012 were analyzed and extrapolated to the German population. Incident cases were defined as follows: diagnostic code A50.x, A51.x, A52.x or A53.x, identifier “G” indicating a confirmed diagnosis (16) and the concurrent treatment with a suitable antibiotic (J01CE08, J01AA02, J01DD04) in the corresponding quarter of the year. Informed consent is not required for these analyses in Germany.

We extracted patient data (subject specifier, gender, year of birth, code for current residence, date of begin and end of insurance) and treatment procedures (inpatient, outpatient, medication). Additionally, data on productivity loss were included to assess possible indirect costs using the human capital method. Reported sick leave time of inpatients right before or after the hospitalization was attributed to the inpatient cohort.

Epidemiological Data

The reported *Treponema pallidum*-positive lab results are accessible in a simplified form via the German database SurvStat@RKI 2.0. The number of syphilis cases for 2010, 2011, and 2012 was derived from the database by age (5-year interval), gender and region (17). Residual titers of past infections, suspected double reporting, as well as suspected cases of insufficiently treated syphilis (*syphilis non satis curate*) were excluded from this dataset by RKI prior to the analysis (18).

The reported seroprevalence of syphilis in blood donors was kindly provided by RKI and is based on blood donor surveillance data (9). The number of positive blood donors was calculated based on the reported seroprevalence rates and the corresponding number of blood samples. We only analyzed data on new blood donors as...
repeat blood donors are repeatedly screened. Thus they are less likely to be infected and are considered a low-risk population for blood-borne diseases (19). It should be noted that the statistical power of this small study population would be insufficient for further extrapolations.

**German EQA Schemes for Treponema Pallidum**

Between 2010 and 2012, six EQA surveys for syphilis were conducted by the German Society for Promoting Quality Assurance in Medical Laboratories (INSTAND) in cooperation with the central reference laboratory at the Institute for Laboratory Medicine, Microbiology & Infection Control at the Northwest Medical Center, Frankfurt/Main (Germany) and with the six reference laboratories of the Bacteriologic Infection Serology Study Group of Germany (BISSGG). Previous reports summarize the organization, structure and detailed evaluation procedures of the German EQA program for bacteriologic infection serology (20–22).

Participants can report qualitative and quantitative results together with additional information on the test kit provider, lot number and laboratory equipment used. In this study, the accuracy of the qualitative as well as the quantitative results were evaluated for TPPA, TPHA, VDRL, FTA-abs IgG and FTA-abs IgM. All EQA samples are derived either from patients with a confirmed diagnosis of syphilis or from healthy blood donors, where absence of *Treponema pallidum* antibodies was confirmed prior to the EQA survey.

**Statistical Analysis**

The data on the insured individuals and the epidemiological data were stratified by gender, age (<25, 25–34, 35–44, 45–54 and >54) and, in the case of the health insurance dataset, 5-digit postal codes. The data were standardized to the general population of Germany for the corresponding years. German population data for 2010, 2011, and 2012 were obtained from the official reports published by the Federal Statistical Office (www.destatis.de). Age-distributed annual incidences were calculated. For the model analysis, age standardized incidence rates (ASR) from the health insurance dataset and age standardized seroprevalence rates from the blood donor dataset were calculated for 2010, 2011, and 2012 to allow comparisons to the average age of syphilis patients was highest in the DAK-G cohort and the German population were comparable, while the first-time blood donor cohort was notably younger. The insurance dataset consisted of a higher proportion of women to men than the other two datasets.

To calculate the averages for sensitivity, specificity and accuracy (pass rate) from the German EQA survey data (Supplementary Table 3), the reported diagnoses of sample donors were used as the “gold standard”. Average net sensitivity and average net specificity were calculated by sequential testing (two-stage screening) using TPHA/TPPA or ELISA as the first test and FTA-abs IgG, IgG Blot, IgG ELISA methods or TPHA/TPPA as the second test. This test algorithm is currently recommended in Germany (16, 24). Average sensitivity and average specificity were used to calculate false positives, false negatives, true positives, and true negatives based on the standardized incidence or, in the case of blood donors, the seroprevalence. Positive predictive values (PPV) and negative predictive values (NPV) were calculated using Bayes’ theorem (25).

**Cost Analysis**

For this study, we calculated direct medical costs for inpatient and outpatient treatment, screening, and confirmatory testing, as well as indirect costs from loss of productivity for 1 year. Indirect costs from loss of productivity were calculated using existing German standards (Hanover consent). Our estimates of indirect costs were based on average earnings (€ 3,014) (26) and the median number of productivity days lost for German syphilis patients aged between 18 and 64. Short-term (<3 days) absence from work without a doctor’s note was not included due to lack of data. The serological testing costs for statutory health insurance patients (~90% of the German population) and the blood donor population were calculated using the diagnostic claims code “Einheitlicher Bewertungsmassstab” (EBM) (27), while the costs for the serological tests for the privately insured patients (~10% of the population) were calculated based on “Gebührenordnung für Ärzte” (GoÄ) (28). The percentage of antibiotics prescribed in our insurance dataset were used to calculate medication costs (Supplementary Table 4). We were unable to calculate treatment costs for patients coded with unspecified syphilis (A53.x), since we had no information about the detailed dosage and duration of therapy. Therefore, these patients were excluded from the cost analysis. Total costs calculated from the claims data were extrapolated to the German population.

**RESULTS**

**Summary of Reported Cases of Syphilis From all Datasets**

Table 1 shows the general distribution of syphilis cases in all datasets, including basic characteristics of the corresponding populations. The average ages of the DAK-G cohort and the German population were comparable, while the first-time blood donor cohort was notably younger. The insurance dataset consisted of a higher proportion of women to men than the other two datasets.

The RKI data showed higher male-to-female ratios in the reported incident syphilis cases than the other two datasets, while the average age of syphilis patients was highest in the DAK-G dataset. The age-stratified distribution of the syphilis cases from the individual datasets are presented in Figures 1–3.

The reported cases show the highest number of cases for men in the age group 35–44 years; the highest number of cases for women is between 25 and 34 years. In contrast to the reported cases, the number of incident cases in the DAK-G dataset was highest in the older age groups, especially for women, where most cases were observed in the age group >54 years. The largest proportion of all seropositive new donors was seen in the age group 35–44 for both sexes.
TABLE 1 | Basic characteristics of the datasets used for this model analysis for 2010 to 2012.

|          | 2010       | 2011       | 2012       | Average   |
|----------|------------|------------|------------|-----------|
| (a)      |            |            |            |           |
| Population | 81,751,602 | 80,327,900 | 80,523,746 | 80,867,749 |
| Male to female ratio | 1:1.0      | 1:1.1      | 1:1.1      | 1:1.0     |
| Average age men | 42         | 42         | 42         | 42        |
| Average age women | 44         | 45         | 45         | 45        |
| No. of syphillis cases | 4,077      | 4,633      | 5,012      | 4,574     |
| Incidence rate / 100,000 person-years | 5.0        | 5.8        | 6.2        | 5.7       |
| Male to female ratio | 10.0:1     | 11.8:1     | 12.5:1     | 11.5:1    |
| Average age cases men | 40         | 40         | 40         | 39        |
| Average age cases women | 39         | 39         | 37         | 39        |

|          | 2010       | 2011       | 2012       | Average   |
|----------|------------|------------|------------|-----------|
| (b)      |            |            |            |           |
| Population | 6,119,470  | 5,800,795  | 5,683,710  | 5,867,922 |
| Male to female ratio | 1:1.5      | 1:1.5      | 1:1.5      | 1:1.5     |
| Average age men | 41         | 41         | 41         | 41        |
| Average age women | 48         | 48         | 48         | 48        |
| No. of syphillis cases | 438        | 359        | 317        | 371       |
| Incidence rate / 100,000 person-years | 7.2        | 6.2        | 5.6        | 6.3       |
| Male to female ratio | 2.7:1      | 3.3:1      | 3.1:1      | 3.2:1     |
| Average age cases men | 48         | 47         | 48         | 48        |
| Average age cases women | 66         | 62         | 65         | 65        |

|          | 2010       | 2011       | 2012       | Average   |
|----------|------------|------------|------------|-----------|
| (c)      |            |            |            |           |
| No. of samples from first-time donors | 561,642    | 542,492    | 496,771    | 533,635   |
| Male to female ratio | n.I.       | 1:1.0      | 1:1.0      | 1:1.0     |
| Average age men | n.I.       | n.I.       | n.I.       | 26        |
| Average age women | n.I.      | n.I.       | n.I.       | 26        |
| No. of anti-Treponema positive samples | 236        | 223        | 221        | 227       |
| Seroprevalence / 100,000 blood samples | 42.1       | 41.1       | 44.4       | 42.5      |
| Male to female ratio | 2.2:1      | 1.7:1      | 2.1:1      | 1.9:1     |
| Average age cases men | 1 37       | 37         | 37         | 37        |
| Average age cases women | 1 43       | 41         | 44         | 43        |

Extrapolation to Population Level
The syphilis incidence of the insurance and the donor datasets was extrapolated to the population level by calculation of age standardized rates (ASR), since the age structure of both study populations differs from that of the reference population. The ASR for syphilis incidence based on the insured population dropped from 7.4 [CI: 6.7–8.1] incident cases per 100,000 standardized person-years in 2010 to 5.9 [CI: 5.2–6.5] incident cases per 100,000 standardized person-years in 2012. In the case of first-time donors, the estimated seroprevalence rate rose from 73.7 [CI: 57.4–89.9] cases per 100,000 standardized person-years in 2010 to 82.9 [CI: 64.5 - 101.3] cases per 100,000 standardized person-years (Table 2, Figure 4).

Geographical Distribution of Estimated Cases
Since the insurance dataset contained the patient’s current postal code, it was possible to extrapolate a geographical distribution (30 %), while 3 % of the incident diagnoses were coded congenital syphilis.
of the expected syphilis cases based on the extrapolated and standardized insurance data (Figure 5A).

The highest standardized incidence was estimated for Berlin (> 12 expected cases per 100,000 standardized person-years). Hamburg, Bremen, North Rhine-Westphalia, Hesse and Rhineland-Palatinate showed between 6 and 12 expected cases per 100,000 standardized person-years. All other federal states showed a lower estimated incidence rate. This distribution is in line with the Germany-wide pattern of the actual incidence cases reported to RKI (Figure 5B).

Results From Germany’s Proficiency Testing Program

We analyzed the data from six Europe-wide EQA surveys for Treponema pallidum antibodies conducted between 2010 and 2012. In this period, an average of 1,033 laboratory results were reported per year (2010: 892; 2011: 1,191; 2012: 1,014). The mean accuracy rate of the qualitative test results (96.4 %; range 78.0–100 %) was slightly higher than that of the quantitative test results (94.0 %, range 74.5–100 %). The accuracy rate for the different detection methods used in the EQA schemes is displayed in Figure 6.

In terms of the qualitative results, the cardiolipin detection had the highest average accuracy (98.6 %, range 91.7–100 %) and the IgG-ELISA had the lowest (94.0 %, range 78.0–97.6 %). In the case of the quantitative results, Cardiolipin tests also showed the
highest average accuracy (98.0%, range 88.5–100%) and the IgG-FTA-abs detection methods showed the lowest average accuracy rate (90.6%, range 74.5–100%).

All serum samples used in these EQA schemes were derived from single donors with a clear clinical history (20–22), which enables the basic performance parameters for the different test methods to be calculated for the model. The observed average sensitivity for the recommended sequential testing for syphilis via qualitative test methods was 92.8% and the combined specificity was 99.9%.

**Assessment of Possible Effect of Test Quality on Estimated Cases**

Our estimated incidence rate for syphilis (6.5/100,000 standardized person-years) would result in an estimated 5,256 syphilis cases for the German reference population. In our model, the average sensitivity (92.8%) and specificity (99.9%) of sequential screening for syphilis antibodies in the EQA results leads to 4,880 true positive and 64,195 false positive cases. The specificity 80,798,298 true negative and 377 false negative test results in the German reference population.
FIGURE 6 | Average accuracy rate of test results for each test used in the EQA surveys, 2010 to 2012. (A) Average accuracy of qualitative test results. Bar markers indicate the range of results. (B) Average accuracy of quantitative test results. Bar markers indicate the range of results. Blot and ELISA tests were not performed as part of the quantitative diagnostic testing for syphilis.
These quality parameters of the test algorithm and the estimated average incidence for syphilis in Germany would result in a PPV of 7.1 % and an NPV of > 99.9 % if the test algorithm were used for population-wide screening purposes.

When the estimated seroprevalence based on first-time blood donors (78.2/100,000 standardized person-years) was used to calculate both PPV and NPV for a possible population-based screening for seroprevalence of syphilis antibodies, the PPV would increase to 47.7 % while the NPV would remain at > 99.9 %.

**Economic Evaluation of the Insured Population**

Based on the insurance dataset, we calculated the average annual direct and indirect costs for syphilis in our insurance population.

Between 2010 and 2012, an average of 72,234 tests were performed each year (TPHA/TPPA & ELISA: 93 %, VDRL test: 7 %, FTA-abs IgG test & blots: 1 %). As the average cost for testing statutory insured outpatients was €4.96 per test, the average annual costs for screening and confirmatory testing amounted to €358,087.

In the insured population, an average of 312 incident cases of syphilis, without syphilis connata were diagnosed in an outpatient setting. 108 cases were treated as early and 106 as late syphilis; both groups were treated with benzathine penicillin, doxycycline and ceftriaxone in accordance with German treatment guidelines (12). Since the exact treatment regime of the average 98 patients with unspecified syphilis (A53.x) was unknown, they were excluded from this analysis.

The average annual per-patient cost of benzathine penicillin, doxycycline or ceftriaxone in outpatients was calculated at €33.24, €9.40 and €184.70 respectively for early syphilis and €99.72, €18.80 and €258.58 respectively for late syphilis. This led to an estimated average annual cost for early and late outpatient treatment of €3,584 and €3,455 respectively. The average annual number of inpatients was 49 patients with an individual median length of stay of 6 days per year (min. 1 day, max. 55 days) average annual cost of €118,503.

236 outpatient and 40 inpatient cases in the age group of 18 to 64 years were included in the calculation of productivity loss on the basis of an average cost of €100.40 per sick day in accordance with the Hanover consent. During 2010 and 2012, inpatients were absent from work for a median of 6 days per year and patient (min. 1 day, max. 446 days), while 4.7 % of all observed outpatients were absent from work for a median of 15 days per year and patient (min. 1 day, max. 546 days), resulting in average annual indirect costs of €24,096 for inpatients and €16,705 for outpatients.

Taken together, the average annual burden for our insurance population was €524,430 for the observed period (Table 3).

### Extrapolated Economic Evaluation of Syphilis in Germany

The expected average number of 5,256 incident cases of syphilis per year is based on the German standard population and our estimated incidence rate of 6.5/100,000 standardized person-years. Using the inpatient-outpatient ratio from our insurance population as a reference, this would result in an average of 4,573 outpatients and 683 inpatients annually when extrapolated to the German standard population. This would produce expected treatment costs for outpatients of €99,960. The treatment of the expected inpatients would lead to an average annual economic burden to healthcare of €1,652,466.

Based on our insurance data, it was estimated that an average of 1,006,727 tests would be performed, leading to a total average annual cost for screening and confirmatory testing of €5,787,886 for outpatients. Since about 10 % of the German population is covered by private health insurance, the total estimated costs for laboratory tests consist of €1,296,279 for privately insured persons and €4,491,607 for persons covered by statutory health insurance. The differences in costs were based on the different fee catalogs of the statutory and private health insurance companies in Germany (27, 28).

Based on average population data, 67.2% of all patients were estimated to be of working age (age group 18 to 64 years), leading to a total of 3,074 expected outpatients and 460 expected inpatients. As for social costs, we estimated the total average indirect costs to be €494,375 annually.

Thus, the total average cost of syphilis for the entire German population is estimated to be €8,034,688 annually during our study period (Table 4).

With respect to the cost of screening and testing in the blood donor population, 2,472,587 tests were performed on blood donors in Germany, leading to a further €12,257,422 in screening and confirmatory testing costs.

Taken together, the cost for blood sample screening as well as the number of estimated costs based on health insurance data in our model would result in an estimated annual cost of €20,292,110.

**Table 3**  
Economic burden of syphilis in the insurance study population. Missing data was coded n.I. (no information).

| TABLE 3 | Economic burden of syphilis in the insurance study population. Missing data was coded n.I. (no information). |
| --- | --- |
| **Direct costs** |  |
| Treatment, outpatients (N = 312) |  |
| Early (A51.x) (N = 106) | €3,584 |
| Late (A52.x) (N = 106) | €3,455 |
| Unspecified (A53.x) (N = 98) | n.I. |
| Total treatment, outpatients | €7,039 |
| Screening and confirmatory testing, outpatients (N = 72,234) |  |
| Total screening and confirmatory testing, outpatients | €358,087 |
| Inpatient care (N = 49) | €118,503 |
| Total direct costs | €483,630 |
| **Indirect costs (N = 276)** |  |
| Productivity losses, outpatients (N = 236) | €16,705 |
| Productivity losses, inpatients (N = 40) | €24,096 |
| Total indirect costs | €40,801 |
| **Total cost of syphilis** | €524,430 |

*Productivity losses are costs due to the incapacity to work.*
DISCUSSION

In this paper, we present a multi-dimensional retrospective model analysis that combines several data sources to estimate the expected burden of syphilis on the German healthcare system. This includes an economic estimation, which we evaluated based on data for the years 2010 to 2012.

Since all syphilis-positive diagnoses must be reported anonymously to the RKI, we have an overview of incident cases in Germany. From 2010 to 2012 the incidence rose from 5.7 cases/100,000 inhabitants (11) to an average of 6.5 [CI: 5.8–7.2] incident cases per 100,000 standardized person-years in 2012, with an average of 6.5 [CI: 5.8–7.2] incident cases per 100,000 standardized person-years in this study period.

The higher incidence rate in our insurance cohort in comparison to the reported cases could be an indication of a slight underreporting of syphilis cases in Germany. This could be due to the fact that only positive laboratory results have to be reported (8), not the clinical diagnosis in general, which is why certain data could be missing in the RKI dataset. Furthermore, the RKI data do not include cases of residual titers of past infections, suspected double reporting, or suspected cases of insufficiently treated syphilis (syphilis non satis curate) (18). Taken together, a slightly higher incidence within the claims data was to be expected. This highlights the usefulness of the inclusion of health insurance data in these models, since all the excluded cases can also impact the healthcare system–be it further testing or treatment costs in the case of syphilis non satis curate.

The unusually high number of syphilis cases among the older female insurance population could have several reasons: it could be an artifact within the dataset, or the age group might consist of a higher proportion of women at a higher risk of being infected with syphilis, or it could be a remnant of the surviving World War II generation. Since Treponema pallidum-specific antibodies show a lifelong persistence regardless of treatment status (30), a rising seroprevalence of Treponema pallidum-specific antibodies is not uncommon in aging populations (31–33).

Despite the possible limitations of our dataset, we were able to identify regional hotspots of syphilis infections in the different federal states in Germany in line with the actual reported data. In particular, the higher number of syphilis cases in this region could have been an indicator of a rise in cases since the reported incidence in the federal state of Rhineland-Palatinate rose from 3.8/100,000 person-years to 5.0/100,000 person-years (+ 31.6 %) from 2012 to 2013 (17).

Since the realization that Treponema pallidum could be transmitted via blood, screening tests for syphilis are routinely performed (34) and it is still mandatory for a blood donor sample to be negative for Treponema pallidum antibodies before it can be released for donation (35). In our study period, the mean seroprevalence for Treponema pallidum specific antibodies in first-time blood donors was 42.5/100,000 donations (0.04 % of all samples) and therefore notably higher than the reported incidence rates. These numbers were still considerably low in comparison to other countries, like the USA (36) or less industrialized countries (32, 37, 38). Data from blood donor surveys are a suitable tool for monitoring infectious disease (11, 12) and might reflect the German population better than our insurance cohort alone. We concentrated our model on first-time blood donors since they are less monitored than repeat donors, are often unaware of their behavioral risks (38, 39), and are less likely to be affected by selection bias (36).

After ASR normalization, the seropositive rate rose to an average seroprevalence rate of 78.2 [CI: 61.1-95.4]/100,000 person-years. Since a thorough anamnesis of current and past infections, including syphilis, is mandatory in Germany (35), one could assume that the observed seroprevalence indicates a high factor of underassessment in the German population. But since the anamnesis is mostly done by questionnaires, it is prone to errors or information bias. Other publications have already highlighted the fact that donors sometimes give false or insufficient information about their health history and possible risk factors (40–42). In Germany, a notable number of male seropositive donors stated that their way of potentially becoming infected was having sex with other men (MSM), a group that was originally excluded from blood donations at the time due to their

---

**TABLE 4** | Expected economic burden of syphilis in Germany. Missing data was coded n.I. (no information).

| Description | Cost (€) |
|-------------|---------|
| **Direct costs** | |
| Antibiotic treatment, outpatients (N = 4,573) | |
| Early (A51.x) (N = 1,534) | 50,894 |
| Late (A52.x) (N = 1,505) | 49,086 |
| Unspecified (A53.x) (N = 1,534) | n.I. |
| Total treatment, outpatients | 99,960 |
| **Screening and confirmatory testing, outpatients (N = 1,006,727)** | |
| Statutory insured (N = 906,054) | 4,491,607 |
| Privately insured (N = 100,673) | 1,296,279 |
| Total screening and confirmatory testing, outpatients | 5,787,886 |
| Inpatient care (N = 683) | 1,652,466 |
| **Total direct costs** | 7,540,312 |
| **Indirect costs (N = 3,534)** | |
| Productivity losses, outpatients (N = 3,074) | 217,623 |
| Productivity losses, inpatients (N = 460) | 276,752 |
| **Total indirect costs** | 494,375 |
| **Total cost of syphilis** | 8,034,688 |

*Productivity losses are costs due to the incapacity to work.*
high risk for STIs (12, 29). Therefore, the data might include people from risk groups as well as people who have already recovered from a syphilis infection. As the assessment is made by directly testing for syphilis, which detects lifelong acquired anti-
Treponema antibodies, it is not possible to distinguish between a cured or an active infection, as discussed above with respect to the older insurance cohort.

We used the data on laboratory diagnosis, therapy and days absent from work from the insurance dataset to estimate the possible direct and indirect economic burden of syphilis for Germany in our study period. The average annual costs in our insurance cohort amounted to €524,430 in our study period. When extrapolated to the corresponding German population, this would amount to an estimated total annual economic burden for the diagnosis and treatment of syphilis of €8,034,688.

Combining this with the costs for screening all blood donor samples (first-time and repeated), the total estimated economic burden of syphilis based on our model would amount to €20,292,110. In comparison to the average annual total healthcare costs from 2010 to 2012 as 29,730 Mio. € (https://www.gbe-bund.de/), the individual contribution of syphilis might be small, but one should keep in mind that the general incidence of syphilis in Germany was quite low at that time. A rising incidence could change the importance of this infectious disease within a few years, so these model analyses are a useful tool to estimate the expected economic burden.

In our study we used data from 2010 to 2012, because these data were available for our research. Notably, the average number of reported cases from RKI in the period from 2013 to 2019 was almost doubled in comparison with the average number of reported cases in the period from 2010 to 2012, with a peak of 7880 cases in 2019. This 1.5-fold increase in cases would result in €2.6 treatment costs for in- and outpatients. In addition the test costs would rise to 8.7 mio. Furthermore, from the societal point of view, we projected the total indirect costs to be 681,285 €. Thus, the total average cost of syphilis for the entire German population is projected to be nearly €12 Mio, without including blood donor testing costs.

To test the extrapolations of our insurance cohort, we compared the number of expected syphilis inpatients with the number of actual reported cases. Despite the limitations of our insurance cohort, the extrapolation of an average of 683 expected inpatients per year underestimated the actual number of patients reported under the DRG by 10.8 % (on average 766 cases per year) (43).

Finally, we combined the extrapolated data from the insurance dataset with the accuracy of the test systems observed in the evaluation of international EQA surveys conducted by INSTAND between 2010 and 2012. The EQA schemes for syphilis antibodies are performed with sample material from single donors with a clear medical history (20–22), which makes bias due to matrix effects unlikely.

The various test systems showed high accuracies for qualitative (96.4 %, range: 78.0 %–100 %) and quantitative (94.0, range 74.5–100 %) test results, which are slightly higher than previously reported results (44). Using the known diagnosis for the EQA sample as a gold standard, we calculated the average sensitivity and specificity within the observed period to be 92.8 and 99.9 %, respectively.

The use of the reverse test algorithm for Treponema pallidum on the basis of the reference population would result in 64,195 false-positive results and 377 false-negative results. While the false-negative results could lead to a further rise in syphilis cases due to transmission, the false-positive results would result in overtreatment.

Our study has some limitations. First, the insurance dataset differed from the German reference population with respect to age and male-to-female ratio. German statutory healthcare providers differ in terms of composition (e.g., socio-economic status, gender distribution) and number of members (13); therefore, the use of data from just one insurance institution could not be representative enough and data from further insurance providers should be included in future models to strengthen the validity.

We were unable to adjust for possible differences in socio-economic status of both populations because the information was missing in the DAK-G dataset. A low socio-economic status is a risk factor for syphilis infection (31, 36) and an unnoted difference between both datasets could contribute to the observed differences in the estimated and reported incidence rates. We did not include costs derived from possible coinfections, like HIV, even though an active syphilis infection is a known risk factor for the transmission of HIV (45, 46). This impact could be quite notable due to the high costs of anti-retroviral therapy (47), but we wanted to develop a model focusing on syphilis, which should be more easily transferable to other infectious diseases. Furthermore, we were unable to include the impact of short-term absence from work (> 3 days) since this information was missing as well. The limitation of the blood-donor dataset includes a possible underestimation of the seroprevalence based on this exclusion criteria for risk groups (12). Since we were missing detailed information about the treatment regime for outpatients coded with unspecified syphilis (A53.x), we could not include them in our economic evaluation of the direct costs. This leads to a slight underestimation of direct treatment costs for outpatients.

The strength of our model concerning the linkage of real-life population data, based on claims data from a large statutory health insurance company in Germany, with surveillance data from blood donors and the observed test quality based on international EQA schemes. Futhermore, our results show a good concordance with corresponding DRG data.

These results show the usefulness of claims data in estimating the (economic) burden of a disease on the corresponding healthcare system, especially since they often include data other than health surveys, including most prominently a treatment algorithm. Our model was able to predict the expected number of syphilis inpatients with an accuracy of 89.2 %. The assessment of the ‘real-life’ test quality, as estimated based on our EQA schemes, is a useful tool to further estimate the possible impact of overtreatment and possible underestimation based on test quality.
CONCLUSIONS

The linkage of claims data, results from EQA schemes and screening information, such as blood donor surveillance, can be a useful tool for assessing the burden of certain diseases like syphilis on the healthcare system—including the financial burden and indirect economic burden due to absence from work. This model might help to raise the awareness of health care professionals in special risk populations and may help to estimate the minimum future geographic regions.

Furthermore, it can help to raise awareness in possible at-risk populations and may help to estimate the minimum future budgets. The use of old datasets is useful to test the strengths and weaknesses of such model analysis.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics Committee of Goethe University Frankfurt (Main), which approved the usage of samples from voluntary blood donors to be used for the EQA schemes. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

RŠ, FN, BL, and K-PH contributed to conception and design of the study. RS, NW, LV, and BL performed the statistical analysis. RS and NW wrote the first draft of the manuscript. RŠ and NW share the first authorship. KPH and BL contributed equally to this work and share the last authorship. All authors contributed to manuscript revision, read and approved the submitted version.

FUNDING

The research was performed as part of an employment of the authors and by the INSTAND grant VF-01-KPH-2017.

ACKNOWLEDGMENTS

The authors would like to thank the DAK-G as well as the RIKI for providing the data for this study.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh.2022.883564/full#supplementary-material

REFERENCES

1. WHO. WHO Guidelines for the Treatment of Treponema pallidum (Syphilis). Geneva: World Health Organization 2016. (2016).

2. ECDC. Syphilis and congenital syphilis in Europe: A review of epidemiological trends (2007-2018) and options for response. Stockholm: European Centre for Disease Prevention and Control. (2019).

3. Cohen SE, Klausner JD, Engelman J, Philip S. Syphilis in the modern era: an update for physicians. Infect Dis Clin North Am. (2013) 27:705–22. doi: 10.1016/j.idc.2013.08.005

4. Peeling RW, Hook EW. 3rd. The pathogenesis of syphilis: the Great Mimicker, revisited. J Pathol. (2006) 208:224–32. doi: 10.1002/path.1903

5. Barnett R. Syphilis. Lancet. (2018) 391:1471. doi: 10.1016/S0140-6736(18)30833-X

6. Peeling RW, Mabey D, Kamb ML, Chen XS, Radolf JD, Benzaken AS. Syphilis. Nat Rev Dis Primers. (2017) 3:17073. doi: 10.1038/nrdp.2017.73

7. Ghahem KG, Ram S, Rice PA. The Modern Epidemic of Syphilis. N Engl J Med. (2020) 382:845–54. doi: 10.1056/NEJMra1901593

8. Verbraucherschutz Bfu. Gesetz zur Verhuertung und Bekämpfung von Infektionskrankheiten beim Menschen (Infektionsschutzgesetz - IFSG). Available online at: Bundesministerium fuer Justiz und Verbraucherschutz (2020).

9. Verbraucherschutz Bfu. Gesetz zur Regelung des Transfusionswesens (Transfusionsgesetz - TFG). Available online at: Bundesministerium der Justiz und Verbraucherschutz (accessed 25 Nov, 2020).

10. Robert-Koch-Institut. SurvStat@RKI 2.0: RKI SurvStat. Available online at: https://www.rki.de/DE/Infekt/Blut/Blutsicherheit/FAQ_node.html

11. Use CMPH. Guideline on Epidemiological Data on Blood Transmissible Infections. London: European Medicines Agency. (2010).

12. Offergeld R, Ritter S, Hamouda O. HIV, HCV, HBV and syphilis surveillance among blood donors in Germany 2008-2010. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. (2012) 55:907–13. doi: 10.1007/s00103-012-1516-1

13. Neubauer S, Kreis K, Klora M, Zeidler J. Access, use, and challenges of claims data analyses in Germany. Eur J Health Econ. (2017) 18:533–6. doi: 10.1007/s10198-016-0849-3

14. Sorensen HT, Sabroe S, Olsen J. A framework for evaluation of secondary data sources for epidemiological research. Int J Epidemiol. (1996) 25:435–42. doi: 10.1093/ije/25.2.435

15. Swart E, Gothe H, Geyer S, Jaunzeme J, Maier B, Grobe T, et al. Gute praxis sekundardatenanalyse (GPS): leitlinien und empfehlungen. Das Gesundheitswesen. (2015) 77:120–6. doi: 10.1007/s00103-015-0034-2

16. Schofer H, Enders M, Esser S, Feiterna-Sperling C, Hagodorn HJ, Magistro G, et al. Diagnosis and treatment of syphilis: Update of the S2k guidelines 2020 of the German STI Society (DSTIG) in cooperation with the following specialist societies: DAIG, dagnä, DDG, DGG, DGGH, DGI, DGIN, DGPI, DGU, RKI. Hautarzt. (2020) 71:969–99. doi: 10.1007/s00103-020-04672-6

17. Robert-Koch-Institut. SurvStat@Rki 2.0: Rki. Available online at: https://survstat.rki.de.

18. Koch-Institut R. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten fur. Berlin (2019). Available online at: https://www.rki.de/DE/Content/Infekt/Jahrbuch/index_node.html

19. Baijo AM, Kupek E, Petry A. Syphilis seroprevalence estimates of Santa Catarina blood donors in (2010). Rev Soc Bras Med Trop. (2014) 47:179–85. doi: 10.1590/0037-8682-0302-2014

20. Mai M, Müller I, Hunfeld KF. Qualität bakteriologisch-infektionsserologischer Verfahren in Deutschland: Auswertung der infektionsserologischen Ringversuche 2011 - Beitrag der Qualitätssicherungskommission der Deutschen Gesellschaft für Hygiene und Mikrobiologie. (2014). doi: 10.3205/lab000014

21. Maneg D MI, Hunfeld KP. Ergebnisse des bakteriologischinfektionsserologischen INSTAND-Ringversuchs 2010: Eine zusammenfassende Analyse - Beitrag der Qualitätssicherungskommission der
22. Mai MMI, Walch D, Hunfeld KP. Zur Qualität bakteriologischinfektionseroserologischer Verfahren in Deutschland: Auswertung der infektionseroserologischen Ringversuche (2012). Beitrag der Qualitätssicherungskommission der DGHM, GMS Ger Med Sci. (2016) 7. doi: 10.3205/1e300012

23. Rothman KJS, Greenland SL. Lash Modern Epidemiology 3rd ed. Philadelphia: Lippincott Williams & Wilkins. (2008).

24. Robert-Koch-Institut. Syphilis - Epidemiologie: RKI. (2020). Available online at: https://www.rki.de/DE/Content/Infekt/EpidBull/Markblatter/Ratgeber/Syphilis.html?sessionid=24B2020899A8BF846E0245C34BEBDF4.internet121#doc2382638b0/daytext9.

25. Altman DG, Bland JM. Diagnostic tests 2: Predictive values. Bmj. (1994) 309:102. doi: 10.1136/bmj.309.6947.102

26. Average annual wages in Germany 2000–2017. Statista. Available online at: https://www.statista.com/statistics/416207/average-annual-wages-germany-y-on-y-in-euros/

27. Bundesvereinigung K. Einheitlicher Bewertungsmassstab (EBM). Available online at: https://www.bvb.de/.

28. Krankenversicherung VdP. Gebührenordnung fuer Aerzte (GoA). Available online at: https://www.pkv.de/.

29. Preubel K, Ritter S, Houareau C, Offergeld R. HIV, HCV, HBV- and Syphilis-Infektionen bei Blutspendern 2011-2016. Auswertung der epidemiologischen Daten nach § 22 TFG.

30. Gottlieb SL, Pope V, Sternberg MR, McQuillan GM, Beltrami JE, Berman SM, et al. Prevalence of syphilis seroreactivity in the United States: data from the National Health and Nutrition Examination Surveys (NHANES) 2001-2004. Sex Transm Dis. (2008) 35:507–11. doi: 10.1097/OLQ.0b013e3181644ab8

31. Jitapunkul S. Syphilitic seroreactivity among the Thai population aged 50 years and above: value of mass screening. Southeast Asian J Trop Med Public Health. (2000) 31:349–53.

32. Bisseye C, Eko Mba JM, Ntsame Ndong JM, Kosiorek HE, Butterfield RJ, Mombo LE, et al. Decline in the seroprevalence of syphilis markers among first-time blood donors in Libreville (Gabon) between 2004 and (2016). BMC Public Health. (2019) 19:167. doi: 10.1186/s12889-019-6489-7

33. Wu X, Guan Y, Ye J, Fu H, Zhang C, Lan L, et al. Association between syphilis seroprevalence and age among blood donors in Southern China: an observational study from 2014 to (2017). BMJ Open. (2019) 9:e024393. doi: 10.1136/bmjopen-2018-024393

34. Seidl S. Syphilis screening in the (1990s). Wiley Online Library. (1990). doi: 10.1046/j.1537-2995.1990.30991048779.x

35. Richtlinie zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Richtlinie Hamotherapie). (2017).

36. Kane MA, Bloch EM, Bruhn R, Kaidarova Z, Murphy EL. Demographic determinants of syphilis seroprevalence among U.S. blood donors, 2011-2012. BMC Infect Dis. (2015) 15:63. doi: 10.1186/s12879-015-0805-3

37. M’Baya B, Jumbe V, Samuel V, M’Bwana R, Mangani C. Seroprevalence and trends in transfusion transmissible infections among voluntary non-remunerated blood donors at the Malawi Blood Transfusion Service-a time trend study. Malawi Med J. (2019) 31:118–25. doi: 10.4314/mmj.v31i2.3

38. Pessoni LL, Aquino EC, Alcantara KC. Prevalence and trends in transfusion-transmissible infections among blood donors in Brazil from 2010 to (2016). Hematol Transfus Cell Ther. (2019) 41:310–5. doi: 10.1016/j.hct.2019.03.009

39. Zou S, Stramer SL, Dodd RY. Donor testing and risk: current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations. Transfus Med Rev. (2012) 26:119–28. doi: 10.1016/j.tmrv.2011.07.007

40. Gardella C, Marfin AA, Kahn RH, Swint E, Markowitz LE. Persons with early syphilis identified through blood or plasma donation screening in the United States. J Infect Dis. (2002) 185:545–9. doi: 10.1086/338829

41. Liu S, Luo L, Xi G, Wan L, Zhong L, Chen X, et al. Seroprevalence and risk factors on Syphilis among blood donors in Chengdu, China,from 2005 to (2017). BMC Infect Dis. (2019) 19:509. doi: 10.1186/s12879-019-4128-7

42. Offergeld R, Hamouda O, Burger R. Epidemiological data - an important part of the hemovigilance system. Transfus Med Hemother. (2010) 37:125–30. doi: 10.1159/000314212

43. Destatis SB. Tabelle 23131-0002 Krankenhauspatienten: Deutschland, Jahre, Geschlecht, Altersgruppen. Hauptdiagnose ICD-10 2010-2012. Available online at: https://www-genesis.de/genesis/dg.htm?auswahltext=&nummertext=3&name=GES025&werteabruf=Werteabruf#abreadcumb

44. Muller I, Brade V, Hagedorn HJ, Straube E, Schomer C, Frosch M, et al. Is serological testing a reliable tool in laboratory diagnosis of syphilis? Meta-analysis of eight external quality control surveys performed by the german infection serology proficiency testing program. J Clin Microbiol. (2006) 44:1335–41. doi: 10.1128/JCM.44.4.1335-1341.2006

45. Spinola SM, Orazi A, Arno JN, Fortney K, Kotylo P, Chen CY, et al. Haemophilus ducreyi elicits a cutaneous infiltrate of CD4 cells during experimental human infection. J Infect Dis. (1996) 173:394-402. doi: 10.1093/infdis/173.2.394

46. Wasserheit JN. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis. (1992) 19:61–77. doi: 10.1097/00007435-199219002-00001

47. Stoll M, Claes C, Schulte E. Graf von der Schellenburg JM, Schmidt RE. Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART. Eur J Med Res. (2002) 7:463–71.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Šmit, Wojtalowicz, Vierbaum, Noubarakhsh, Schellenberg, Hunfeld and Lohr. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.